HCPLive staff

A drug which has already been approved for patients with diabetes could have more benefits for people at risk of having heart disease, according a recent study.

A recent study of patients who underwent bariatric surgery showed that even while their weight settled following their procedure their bone loss continued even two years after the operation.

An experimental, first-in-class drug that affects the gut microbiota has been shown to improve glucose tolerance and insulin sensitivity in adults with prediabetes.

A new factor in sleep and sleep apnea among obese and overweight men was introduced by researchers at a recent conference, pointing to the man's testosterone levels as helping determine sleep quality.

Intestinal bacteria levels may be a good marker for determining risk of type 2 diabetes and obesity.

The brains of hyperglycemic patients with Type 1 diabetes produce elevated levels of the neurotransmitter glutamate, which may increase their risk of depression.

Treatment for 12 weeks with empagliflozin led to significant reductions in HbA1c levels and blood pressure compared to placebo.

Researchers have identified a compound that reduces the levels of a key enzyme that regulates activity in pain receptors, pointing the way to new therapies for treating some forms of back pain, shingles, and other types of chronic neuropathic pain.

Study results announced at the 11th European Academy of Dermatology and Venereology Spring Symposium show tofacitinib met its two primary efficacy endpoints.

Study results show that pain associated with osteoarthritis of the knee often exhibits neuropathic pain characteristics.

Study of novel investigational IL-17 receptor antibody meets all primary and secondary endpoints.

Researchers say it may be possible to diagnose and monitor peripheral neuropathy induced by HIV, replacing more invasive methods of testing such as skin biopsy.

Inhaler-delivered drug is a once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.

Study data from two phase 3 clinical trials announced at AAN 2014 show sustained effects one year after two years of treatment with alemtuzumab in patient with MS.

New recommendations support diagnosis and treatment after one unprovoked seizure in patients who have other factors that are associated with a high recurrence risk.

Grastek is the first sublingual allergy immunotherapy product to be approved for use in children as young as age 5.

Bristol Myers-Squibb announced it has submitted new drug applications for the investigational products daclatasvir and asunaprevir for the treatment of patients with genotype 1b hepatitis C.

Gilead's new drug application for a once-daily, fixed dose combination of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C genotype 1 infection in adults has been given priority review by the FDA.

Sodium picosulfate, a commonly prescribed medication for bowel prep prior to colonoscopy, is associated with increased risk of hyponatremia in older adults compared to polyethylene glycol.

Patients undergoing two-year gonadotrophin treatment reported significantly improved physical, social, and psychological quality of life scores.

Hyponatremia is associated with increased mortality and rehospitalization in patients hospitalized for heart failure.

Recently released guidelines seek to provide clarity to the management of hyponatremia by outlining an evidence-based, patient-centered approach to diagnosis and treatment.

Tim Gunn, Pfizer, and Amgen teamed up to offer style and fashion advice for patients who have been diagnosed with psoriasis.